Tubulis announced today that its second drug candidate, TUB-030, has entered clinical evaluation with successful dosing of the first patient in the 5-STAR 1-01 Phase I/IIa...

Through this agreement, Gilead will gain access to Tubulis’ proprietary Tubutecan and Alco5 platforms. The companies will collaborate to select the best technology to...

Tubulis announced today that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to its lead antibody-drug conjugate (ADC) TUB-040 for the...

Tubulis announced today that the first patient has been treated in its first Phase I/IIa trial. The study is evaluating Tubulis’ next-generation antibody-drug conjugate (ADC)...

Tubulis announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing.

Galecto, Inc., a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today...

Tubulis and Bristol Myers Squibb (NYSE: BMY) today announced that they have entered into a strategic license agreement to develop differentiated antibody-drug conjugates...

Domain Therapeutics (“Domain” or “the Company”), a drug discovery and development company focused on G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today...

Galecto., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced today the successful completion of a $64...